Zantrene has been identified as a potent targeted inhibitor of the Fat Mass and Obesity associated protein (FTO).^[1] Previous studies have observed that FTO is over-produced in approximately 50% of metastatic melanomas^[2] and that inhibition of FTO can overcome PD-1 immune checkpoint resistance in mouse melanoma models.^[2,3] PD-1 immune checkpoint inhibitors have emerged as a front-line treatment for many types of cancer, including melanoma. While there have been major advances in melanoma treatments in recent decades, the five-year survival rate for advanced melanoma remains low.^[4]

Race CSO Dr Daniel Tillett said: "These interim results are highly encouraging and support our clinical plans for Zantrene, with the correlation between FTO overexpression and sensitivity to Zantrene suggesting a strong anti-FTO therapeutic opportunity. The high sensitivity of many of the melanoma cell lines to Zantrene as a single agent at concentrations well below chemotherapeutic doses is unexpected and may offer new treatment options for melanoma patients."

Race CEO & MD Phillip Lynch said: "While challenged by COVID-19 related shutdowns we appreciate the encouraging and continued work from the team at the University of Newcastle. Zantrene continues to positively surprise us – we are very pleased with these early results. Melanoma remains a difficult cancer to treat, and one that's of particular relevance to the Australian community, so as we continue with this work, we look forward to learning more about our potential to offer new treatment options to patients."